FDA Accepts Application Covering 64 SKUs, Moving Sesh Closer to Potential Marketing Authorization
Sesh Products US, Inc. has announced a significant regulatory milestone in its efforts to bring its nicotine pouch products to the U.S. market. The company confirmed that the U.S. Food and Drug Administration (FDA) has officially accepted its bundled Premarket Tobacco Product Application (PMTA) for filing. This application, which covers a total of 64 stock-keeping units (SKUs), has successfully passed the FDA’s initial filing review stage and is now set to advance into the substantive scientific review phase—one of the final and most critical steps before a marketing authorization decision is made.
The PMTA pathway is a mandatory regulatory process for any company seeking to market new tobacco or nicotine products in the United States. Under Section 910 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), manufacturers must demonstrate that their products are appropriate for the protection of public health. This involves submitting extensive scientific data, including information on product composition, toxicology, behavioral impact, and population-level health considerations. The FDA evaluates whether the benefits of the product—particularly for adult smokers—outweigh the potential risks, including youth initiation.
For Sesh Products US Inc., reaching this stage represents a meaningful advancement in a highly rigorous and competitive regulatory process. The FDA’s filing determination indicates that the agency has reviewed the application for completeness and found it sufficiently detailed to proceed. This does not imply approval, but it confirms that the submission meets the necessary administrative and scientific thresholds required for deeper evaluation.
The bundled PMTA submitted by Sesh encompasses its Sesh+ line of nicotine pouches. These products are offered in a variety of flavors, nicotine strengths, and packaging formats, targeting adult consumers aged 21 and older who are seeking alternatives to traditional combustible tobacco products. By bundling multiple SKUs into a single application, the company aims to streamline the regulatory review process while demonstrating consistency and scalability across its product portfolio.
The transition into the substantive scientific review phase is particularly important. At this stage, the FDA’s Center for Tobacco Products (CTP) conducts an in-depth analysis of the scientific evidence provided. This includes assessing the product’s potential health risks, its likelihood of helping adult smokers switch from more harmful products, and its potential appeal to non-users, especially youth. The agency may also request additional data, clarifications, or analyses during this phase, making it an interactive and often lengthy process.
According to Sesh, the acceptance of its application reflects years of dedicated scientific research, product development, and regulatory engagement. The company has emphasized its commitment to building a strong evidence base to support the public health profile of its nicotine pouches. This includes studies on toxicological exposure, user behavior, and comparative risk relative to traditional tobacco products.
Max Cunningham, CEO of Sesh, highlighted the importance of this milestone, noting that clearing the filing review is a testament to the company’s sustained efforts and collaboration with regulatory authorities. He described the process as both rigorous and essential, underscoring the company’s intention to continue working closely with the FDA throughout the remaining stages of review. Cunningham also emphasized Sesh’s ambition to secure a marketing order and establish itself as a credible, independent U.S.-based brand in the rapidly evolving nicotine pouch category.
The nicotine pouch market has grown significantly in recent years, driven by increasing consumer interest in smoke-free alternatives. However, it remains a tightly regulated space, particularly in the United States, where the FDA has taken a cautious and evidence-based approach to authorizing new products. Only a limited number of nicotine products have successfully navigated the PMTA process to date, making each advancement noteworthy.
Sesh’s progress also highlights the broader challenges faced by independent companies in this sector. Unlike larger multinational tobacco firms, smaller players often have fewer resources to dedicate to the extensive scientific and regulatory requirements of the PMTA process. As such, reaching the substantive review phase can be seen as a strong indicator of both organizational capability and commitment to compliance.
Looking ahead, the outcome of the FDA’s substantive scientific review will determine whether Sesh’s nicotine pouches can be legally marketed in the United States. If the agency concludes that the products meet the statutory standard of being “appropriate for the protection of public health,” it may issue a marketing granted order (MGO). Conversely, if the evidence is deemed insufficient or if the risks outweigh the benefits, the application may be denied.
During this final phase, Sesh has indicated that it is prepared to respond promptly to any questions or data requests from the FDA. This ongoing dialogue is a critical component of the review process, as it allows the agency to fully evaluate the application and ensures that all relevant scientific considerations are addressed.
In summary, the FDA’s acceptance of Sesh Products US, Inc.’s bundled PMTA for filing marks a pivotal step in the company’s regulatory journey. By advancing to the substantive scientific review phase, Sesh moves closer to a potential marketing authorization, though significant evaluation still lies ahead. The development underscores both the complexity of the PMTA process and the importance of rigorous scientific evidence in shaping the future of nicotine and tobacco products in the U.S. market.
About the PMTA Process
Established under the Family Smoking Prevention and Tobacco Control Act, the PMTA process requires manufacturers to demonstrate that permitting the marketing of a new tobacco product is appropriate for the protection of public health. A filing decision is a threshold determination that an application is complete enough for substantive review; it does not reflect an FDA evaluation of the adequacy of the data contained in the PMTA and does not constitute a marketing order.
About Sesh
Sesh Products US, Inc., a wholly owned subsidiary of Sesh Products Inc., develops modern oral nicotine products for adult consumers. The company holds a granted USPTO patent on its Sesh+ pouch technology and has an active presence across major U.S. convenience retail chains
